Wockhardt Limited has officially announced the appointment of three seasoned pharmaceutical leaders to its senior management team, effective May 4, 2026. The company has designated new leadership for its India Business, Emerging Markets, and Biotechnology divisions. These strategic appointments reflect the firm’s focus on advancing its global biopharmaceutical research and scaling commercial operations across diverse markets, underscoring its commitment to long-term growth and innovation in the healthcare sector.
Key Strategic Appointments
On May 4, 2026, the Board of Directors of Wockhardt Limited identified and designated three key executives as Senior Management Personnel to drive the company’s strategic goals. These appointments are part of an organizational initiative to bolster leadership in specialized pharmaceutical and biotechnology segments.
Leadership Profiles
The newly designated senior leaders bring extensive industry expertise to their respective roles:
- Ms. Annapurna Das: Appointed as President (India Business & Emerging Markets (NCE)). With over 26 years of experience, Ms. Das has a proven track record in driving business transformation and commercial operations at organizations including Takeda India, Sanofi, and MSD.
- Mr. Om Narayan: Appointed as Senior Vice President (Biotech Research Centre). Mr. Narayan holds a Master’s degree in Biotechnology and brings nearly three decades of experience across R&D, biosimilars, and vaccine development, having held leadership roles at major firms like Serum Institute of India and Mylan.
- Mr. Sunil Soni: Appointed as Senior Vice President (Biotechnology). Mr. Soni holds a Master’s degree in Bio-Chemical Engineering & Biotechnology and offers three decades of rich experience in manufacturing operations, process development, and facility commissioning, with prior leadership tenures at Biological E. and Concord Biotech.
Strategic Vision
These appointments are set to provide deep expertise in general management, biopharmaceutical R&D, and large-scale manufacturing operations. By integrating these seasoned professionals into its senior leadership, Wockhardt aims to enhance its competitive edge in the global biosimilar and vaccine landscape, while fostering robust growth in India and other key emerging markets.
Source: BSE
